UBS Remains a Buy on Novo Nordisk (0QIU)
UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...
Barron's3d
Novo Nordisk A/S ADR
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...